mdanderson.org
May 19, 2025, 15:26
New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM
MD Anderson Cancer Center shared a post on LinkedIn:
“New research from MD Anderson shows that teclistamab, a bispecific antibody, is safe and effective for older patients with relapsed/refractory multiple myeloma. In a study led by our Dr. Oren Pasvolsky and Dr. Hans Lee, patients ages 75 and older experienced similar safety and better progression-free survival compared to younger patients. These findings may help expand access to this promising therapy for older adults.”
More posts featuring MD Anderson Cancer Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 9, 2025, 04:15
Jun 9, 2025, 04:06
Jun 9, 2025, 03:59
Jun 9, 2025, 03:26
Jun 9, 2025, 03:08
Jun 9, 2025, 02:00
Jun 8, 2025, 17:03